Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Website: ikenaoncology.com



Growth: Bad revenue growth rate -80.0%, there is slowdown compared to average historical growth rates 19.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -855.6%. On average the margin is decreasing steadily. Gross margin is high, +88.9%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 8.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 1 566.0% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -40.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: IKNA
Share price, USD:  (0.0%)17.16
year average price 15.16  


year start price 1.37 2025-06-12

min close price 1.24 2025-07-22

max close price 17.16 2025-07-28

current price 17.16 2026-06-11
Common stocks: 40 630 101

Dividend Yield:  0.0%
EV / Sales: 65.4x
Margin (EBITDA LTM / Revenue): -855.6%
Fundamental value created in LTM:
Market Cap ($m): 697
Net Debt ($m): -109
EV (Enterprise Value): 588
Price to Book: 5.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-15globenewswire.com

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

2024-12-30zacks.com

Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade

2024-11-07globenewswire.com

Ikena Oncology Reports Third Quarter 2024 Financial Results

2024-05-28globenewswire.com

UPDATE – Ikena Oncology Announces Strategic Update

2024-04-10GlobeNewsWire

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

2024-01-24Zacks Investment Research

Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround

2023-06-20Zacks Investment Research

Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why

2023-06-02Zacks Investment Research

Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why

2023-05-24GlobeNewsWire

Ikena Oncology to Participate in Upcoming Investor Conferences

2023-05-15Zacks Investment Research

Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-07-24 2024-11-07 2024-08-08 2024-05-13 2023-11-09 2023-08-10 2023-05-15 2022-11-07
acceptedDate 2025-11-12 07:30:52 2025-07-24 17:17:25 2025-03-06 08:10:51 2024-11-07 08:00:21 2024-08-08 16:05:27 2024-05-13 16:33:11 2024-03-12 07:30:33 2023-11-09 07:30:26 2023-08-10 07:00:57 2023-05-15 06:04:02 2023-03-14 06:04:14 2022-11-07 07:31:09 2022-03-17 06:31:28 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 0 0 0 0 9M 1M 2M 5M 16M 6M 31M 9M
costOfRevenue 0 87 000 490 000 0 92 000 219 000 1M 242 000 586 000 0 64M 0 47M 45M
grossProfit 0 -87 000 -490 000 0 -92 000 -219 000 8M 943 000 1M 5M 14M 6M -16M -36M
grossProfitRatio 0 0 0 0 0 0.796 0.708 1 1
researchAndDevelopmentExpenses 16M 4M 30M 7M 10M 9M 60M 1M 15M 16M 64M 19M 47M 45M
generalAndAdministrativeExpenses 11M 4M 24M 5M 5M 6M 25M 6M 5M 5M 22M 5M 18M 9M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 11M 4M 24M 5M 5M 6M 25M 6M 5M 5M 22M 5M 18M 9M
otherExpenses 0 309 000 0 812 000 235 000 -7000 -1M 13M -6000 566 000 -2M 0 -47M -45M
operatingExpenses 27M 9M 54M 12M 15M 15M 84M 21M 20M 21M 84M 24M 18M 9M
costAndExpenses 0 9M 55M 12M 15M 16M 85M 21M 20M 21M 87M 24M 65M 54M
interestIncome 0 1M 7M 0 0 0 7M 2M 1M 730 000 2M 576 000 23 000 0
interestExpense 96 000 0 0 0 0 0 0 0 0 -1M 0 576 000 0 0
depreciationAndAmortization 0 87 000 490 000 90 000 92 000 219 000 1M 242 000 242 000 231 000 751 000 213 000 544 000 300 000
ebitda -25M -3M -49M -12M -15M -15M -74M -20M -20M -15M -70M -18M -34M -44M
ebitdaratio 0 0 0 0 0 -16.458 -9.795 -2.877 -2.759
operatingIncome -27M -9M -59M -12M -15M -16M -75M -20M -18M -16M -71M -18M -34M -45M
operatingIncomeRatio 0 0 0 0 0 -16.458 -9.227 -2.92 -2.792
totalOtherIncomeExpensesNet 2M 6M 10M 2M 2M -475 000 7M 2M 1M 1M 2M 538 000 23 000 263 000
incomeBeforeTax -25M -3M -49M -10M -14M -16M -68M -17M -17M -14M -69M -17M -34M -44M
incomeBeforeTaxRatio 0 0 0 0 0 -14.635 -8.54 -2.676 -2.708
incomeTaxExpense 772 000 15 000 152 000 10000 62 000 27 000 -162 000 -242 000 -1M -1M 0 -538 000 0 0
netIncome -26M -3M -49M -10M -14M -16M -68M -17M -17M -13M -69M -17M -34M -44M
netIncomeRatio 0 0 0 0 0 -14.635 -8.54 -2.432 -2.624
eps -0.53 -0.057 -1.02 -0.21 -0.28 -0.33 -1.63 -0.4 -0.44 -0.36 -1.9 -0.46 -0.95 -3.16
epsdiluted -0.53 -0.057 -0.21 -0.28 -0.33 -0.4 -0.44 -0.36 -0.46
weightedAverageShsOut 48M 48M 48M 48M 48M 48M 42M 43M 39M 36M 36M 36M 36M 14M
weightedAverageShsOutDil 48M 48M 48M 48M 48M 48M 42M 43M 39M 36M 36M 36M 36M 14M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-06 2024-03-12 2023-03-14 2022-03-17 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 7M 7M 2M 23 000 0
ebit -49M -75M -71M -34M -45M
nonOperatingIncomeExcludingInterest -5M 0 0 0 0
netIncomeFromContinuingOperations -49M -68M -69M -34M -44M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -49M -68M -69M -34M -44M
epsDiluted -1.02 -1.63 -1.9 -0.95 -3.16

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-07-24 2024-11-07 2024-08-08 2024-05-13 2023-11-09 2023-08-10 2023-05-15 2022-11-07
acceptedDate 2025-11-12 07:30:52 2025-07-24 17:17:25 2025-03-06 08:10:51 2024-11-07 08:00:21 2024-08-08 16:05:27 2024-05-13 16:33:11 2024-03-12 07:30:33 2023-11-09 07:30:26 2023-08-10 07:00:57 2023-05-15 06:04:02 2023-03-14 06:04:14 2022-11-07 07:31:09 2022-03-17 06:31:28 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 103M 58M 39M 45M 44M 53M 120M 121M 71M 29M 60M 67M 232M 162M
shortTermInvestments 39M 37M 85M 93M 101M 104M 56M 76M 86M 108M 97M 107M 0 0
cashAndShortTermInvestments 143M 96M 124M 138M 145M 157M 175M 197M 157M 138M 157M 174M 232M 162M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 5M 3M 3M 4M 4M 4M 1M 1M 731 000 1M 964 000 1M 629 000 2M
totalCurrentAssets 148M 99M 127M 142M 149M 161M 179M 201M 161M 141M 160M 178M 237M 166M
propertyPlantEquipmentNet 884 000 3M 4M 5M 6M 6M 8M 11M 7M 8M 8M 9M 9M 2M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 1M 1M 0 1M 4M 0 0 0 2M 872 000
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 12M 24M 10M 3M 1M 4M 5M 3M 0 3M 4M 4M 0 0
totalNonCurrentAssets 13M 27M 14M 7M 8M 12M 13M 15M 11M 11M 12M 12M 11M 2M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 161M 126M 142M 149M 157M 173M 192M 215M 172M 152M 172M 190M 248M 168M
accountPayables 2M 512 000 897 000 2M 1M 2M 2M 4M 2M 3M 2M 2M 2M 2M
shortTermDebt 2M 8M 0 4M 7M 3M 0 3M 2M 2M 0 2M 2M 186 000
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 659 000 2M 4M 9M 12M 17M 21M
otherCurrentLiabilities 7M -856 000 2M 4M -602 000 5M 3M 11M 6M 5M 5M 9M 1M -186 000
totalCurrentLiabilities 11M 7M 11M 9M 8M 10M 14M 19M 12M 14M 22M 25M 27M 28M
longTermDebt 1M 2M 0 4M 5M 6M 0 8M 3M 3M 0 4M 0 206M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 3M 8M 35M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 -8M 0
otherNonCurrentLiabilities 9M 1M 1M 1M 1M 963 999 950 000 33M 0 0 0 -10M 8M 0
totalNonCurrentLiabilities 10M 3M 5M 6M 6M 7M 8M 41M 3M 3M 4M 7M 13M 241M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 6M 8M 8M 9M 6M 11M 11M 5M 5M 6M 6M 7M 186 000
totalLiabilities 21M 10M 16M 15M 15M 17M 22M 60M 15M 17M 25M 32M 40M 269M
preferredStock 161M 0 0 0 0 0 0 32M 0 0 0 0 248M 206M
commonStock 11 000 48 000 48 000 48 000 48 000 48 000 48 000 44 000 42 000 36 000 36 000 36 000 36 000 3000
retainedEarnings -223M -343M -332M -322M -312M -299M -282M -263M -246M -228M -214M -200M -145M -111M
accumulatedOtherComprehensiveIncomeLoss 94 000 65 000 68 000 240 000 -350 000 -313 000 -48 000 -290 000 -456 000 -491 000 -763 000 -1M -248M -206M
othertotalStockholdersEquity 363M 459M 456M 455M 454M 387M 403M 364M 360M
totalStockholdersEquity 140M 116M 126M 134M 143M 155M 170M 155M 157M 135M 147M 159M 208M -101M
totalEquity 140M 116M 126M 134M 143M 155M 170M 155M 157M 135M 147M 159M 208M -101M
totalLiabilitiesAndStockholdersEquity 161M 126M 149M 157M 173M 215M 172M 152M 190M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 161M 126M 142M 149M 157M 173M 192M 215M 172M 152M 172M 190M 248M 168M
totalInvestments 0 37M 85M 93M 102M 106M 56M 76M 86M 108M 97M 107M 2M 872 000
totalDebt 3M 6M 8M 8M 9M 10M 11M 11M 5M 5M 6M 6M 7M 186 000
netDebt -100M -53M -32M -37M -35M -43M -109M -110M -66M -24M -54M -61M -225M -162M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-06 2024-03-12 2023-03-14 2022-03-17 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 2M 2M 4M 2M
totalPayables 897 000 2M 2M 2M 2M
otherPayables 0 0 0 0 0
accruedExpenses 4M 5M 3M 3M 5M
capitalLeaseObligationsCurrent 4M 4M 2M 2M 186 000
capitalLeaseObligationsNonCurrent 4M 7M 4M 5M 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 457M 452M 362M 353M 10M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA IKNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-12 2025-07-24 2024-11-07 2024-08-08 2024-05-13 2023-11-09 2023-08-10 2023-05-15 2022-11-07
acceptedDate 2025-11-12 07:30:52 2025-07-24 17:17:25 2025-03-06 08:10:51 2024-11-07 08:00:21 2024-08-08 16:05:27 2024-05-13 16:33:11 2024-03-12 07:30:33 2023-11-09 07:30:26 2023-08-10 07:00:57 2023-05-15 06:04:02 2023-03-14 06:04:14 2022-11-07 07:31:09 2022-03-17 06:31:28 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -27M -3M -49M -10M -14M -16M -68M -17M -17M -14M -69M -17M -34M -44M
depreciationAndAmortization -201 000 87 000 490 000 90 000 92 000 219 000 1M 242 000 242 000 231 000 751 000 213 000 544 000 300 000
deferredIncomeTax 0 0 0 0 0 0 0 -577 000 -597 000 0 0 0 0 0
stockBasedCompensation 14M 458 000 5M 1M 1M 2M 8M 2M 2M 2M 8M 2M 5M 2M
changeInWorkingCapital 5M -2M -4M 5M -181 000 -5M -22M -5M -3M -8M -15M -2M -33M -8M
accountsReceivables 0 0 0 658 000 -501 000 -157 000 -3M -666 000 -987 000 666 000 -291 000 -1M 361 000 519 000
inventory 0 0 0 0 0 0 0 666 000 987 000 0 0 0 -361 000 -519 000
accountsPayables -2M -293 000 -1M 132 000 -501 000 -157 000 -3M -666 000 -987 000 666 000 -291 000 0 361 000 519 000
otherWorkingCapital 5M -1M -3M 5M 320 000 -5M -19M -4M -2M -9M -15M -1M -33M -8M
otherNonCashItems -18M 494 000 1M -5M 2M 3M 1M 471 000 344 000 -193 000 2M 371 000 1M 12M
netCashProvidedByOperatingActivities -27M -3M -46M -9M -13M -18M -80M -20M -18M -20M -74M -17M -60M -38M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 -414 000 0 -4000 -152 000 -1M -1M -2M -766 000
acquisitionsNet 0 0 0 -245 000 185 000 60 000 0 0 4000 0 98M 0 0 4M
purchasesOfInvestments 22M -6M -88M -9M -10M -62M -90M -18M -5M -42M -216M -15M 0 0
salesMaturitiesOfInvestments -69M 46M 60M 18M 14M 14M 155M 50M 28M 31M 118M 52M 0 0
otherInvestingActivites 10M -15M 435 000 185 000 -49M 32M 4000 0 0
netCashUsedForInvestingActivites -37M 25M 9M 4M -49M 32M 23M -11M 36M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 71M 0 0 0 0 -123 000 38M 0 0
commonStockRepurchased 0 0 0 0 0 0 -663 000 -108 000 -663 000 0 0 0 0 -57 000
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 135M 0 0 0 0 39M 0 0 24 000
netCashUsedProvidedByFinancingActivities 135M 0 0 0 0 39M 37M 0 24 000
effectOfForexChangesOnCash 652 000 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 44M 22M -81M 2M -9M -67M 60M 51M 42M -31M -172M 19M 70M 81M
cashAtEndOfPeriod 103M 59M 40M 46M 44M 53M 121M 123M 72M 30M 61M 68M 233M 163M
cashAtBeginningOfPeriod 59M 38M 121M 44M 53M 120M 61M 72M 30M 61M 233M 49M 163M 82M
operatingCashFlow -27M -3M -46M -9M -13M -18M -80M -20M -18M -20M -74M -17M -60M -38M
capitalExpenditure 0 0 0 0 0 0 -414 000 0 -4000 -152 000 -1M -1M -2M -766 000
freeCashFlow -27M -3M -46M -9M -13M -18M -80M -20M -18M -20M -76M -18M -62M -39M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-06 2024-03-12 2023-03-14 2022-03-17 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -7M 0 -98M 0 0
netCashProvidedByInvestingActivities -35M 64M -99M -2M 3M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 77M 1M 131M 116M
netCommonStockIssuance 0 37M 1M 131M -57 000
commonStockIssuance 0 37M 1M 131M 0
netPreferredStockIssuance 0 40M 0 -146 000 116M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 -808 000 0 582 000 70 000
netCashProvidedByFinancingActivities 0 76M 1M 132M 116M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2024-11-07 13:30 ET
Ikena Oncology Reports Third Quarter 2024 Financial Results
2024-08-08 20:15 ET
Ikena Oncology Reports Second Quarter 2024 Financial Results
2024-05-28 20:15 ET
Ikena Oncology Announces Strategic Update
2024-05-13 20:45 ET
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
2024-04-10 12:00 ET
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
2024-03-12 12:00 ET
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 13:00 ET
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
2024-02-21 21:15 ET
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
2024-01-18 21:05 ET
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
2023-11-09 12:00 ET
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
2023-11-07 13:00 ET
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
2023-09-05 12:00 ET
Ikena Oncology to Participate in September 2023 Investor Conferences
2023-08-10 12:00 ET
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
2023-08-07 11:00 ET
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
2023-05-24 12:00 ET
Ikena Oncology to Participate in Upcoming Investor Conferences
2023-05-15 11:50 ET
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
2023-05-15 11:45 ET
Ikena Oncology Announces $40 Million Underwritten Offering
2023-04-20 12:00 ET
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
2023-04-17 13:00 ET
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
2023-03-14 11:00 ET
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
2023-03-07 13:00 ET
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
2023-03-06 13:00 ET
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
2023-02-28 13:00 ET
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
2022-12-19 21:30 ET
Ikena Oncology Appoints Owen Hughes as Board Chair
2022-11-28 13:00 ET
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
2022-11-22 12:30 ET
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
2022-11-10 14:00 ET
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
2022-11-07 13:05 ET
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
2022-10-26 11:30 ET
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
2022-10-18 11:30 ET
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
2022-10-05 12:05 ET
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
2022-09-06 11:30 ET
Ikena Oncology to Participate in September 2022 Investor Conferences
2022-08-11 11:30 ET
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
2022-07-06 11:00 ET
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022
2022-06-22 11:00 ET
Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
2022-05-18 11:00 ET
Ikena Oncology to Participate in Spring 2022 Investor Conferences
2022-05-12 11:00 ET
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update
2022-05-02 11:00 ET
Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration
2022-04-28 11:00 ET
Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
2022-04-13 11:00 ET
Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development
2022-03-17 11:00 ET
Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
2022-03-07 21:30 ET
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
2022-03-01 12:00 ET
Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference
2022-01-26 12:00 ET
Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors
2021-12-08 12:00 ET
Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
2021-11-12 12:00 ET
Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175
2021-11-10 12:00 ET
Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update
2021-11-04 11:00 ET
Ikena Oncology to Participate in November 2021 Virtual Investor Conferences
2021-11-02 12:00 ET
Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930
2021-10-07 13:00 ET
Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
2021-10-01 12:15 ET
Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
2021-09-02 11:00 ET
Ikena Oncology to Participate in September 2021 Virtual Investor Conferences
2021-08-12 11:00 ET
Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs
2021-07-08 11:00 ET
Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021
2021-05-26 11:00 ET
Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference
2021-05-13 11:00 ET
Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021
2021-04-15 11:00 ET
Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors
2021-03-30 20:05 ET
Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2021-03-26 00:55 ET
Ikena Oncology Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2026-04-13 11:10 ET
Ikena Oncology, Inc. published news for 2026 q1
SEC form 8
2026-04-13 11:10 ET
Ikena Oncology, Inc. published news for 2026 q1
SEC form 8
2026-04-13 11:10 ET
Ikena Oncology, Inc. published news for 2026 q1
SEC form 8
2026-04-13 11:10 ET
Ikena Oncology, Inc. published news for 2026 q1
SEC form 10
2026-03-10 12:33 ET
Ikena Oncology, Inc. published news for 2025 q4
SEC form 8
2026-03-10 12:16 ET
Ikena Oncology, Inc. published news for 2025 q4
SEC form 8
2026-03-10 12:16 ET
Ikena Oncology, Inc. published news for 2025 q4
SEC form 8
2025-11-19 12:50 ET
Ikena Oncology, Inc. published news for 2025 q3
SEC form 8
2025-11-19 12:50 ET
Ikena Oncology, Inc. published news for 2025 q3
SEC form 10
2025-11-12 07:30 ET
Ikena Oncology, Inc. reported for 2025 q3
SEC form 8
2025-11-12 07:25 ET
Ikena Oncology, Inc. published news for 2025 q3
SEC form 8
2025-11-12 07:25 ET
Ikena Oncology, Inc. reported for 2025 q3
SEC form 8
2025-08-12 21:19 ET
Ikena Oncology, Inc. reported for 2025 q2
SEC form 8
2025-08-12 21:19 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-08-12 21:19 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-08-05 21:15 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-08-05 21:15 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-07-25 16:23 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-07-25 16:23 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 10
2025-07-24 21:17 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-07-11 12:34 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-07-11 12:34 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-07-01 20:15 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 8
2025-07-01 20:15 ET
Ikena Oncology, Inc. published news for 2025 q2
SEC form 10
2025-05-08 12:00 ET
Ikena Oncology, Inc. reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Ikena Oncology, Inc. reported for 2025 q1
SEC form 10
2025-03-06 13:10 ET
Ikena Oncology, Inc. reported for 2024 q4
SEC form 10
2025-03-06 00:00 ET
Ikena Oncology, Inc. reported for 2024 q4
SEC form 10
2024-11-07 08:00 ET
Ikena Oncology, Inc. published news for 2024 q3
SEC form 10
2024-08-08 16:05 ET
Ikena Oncology, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Ikena Oncology, Inc. published news for 2024 q2
SEC form 10
2024-05-13 16:33 ET
Ikena Oncology, Inc. reported for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Ikena Oncology, Inc. reported for 2024 q1
SEC form 10
2024-03-12 07:30 ET
Ikena Oncology, Inc. reported for 2023 q4
SEC form 10
2024-03-12 00:00 ET
Ikena Oncology, Inc. reported for 2023 q4
SEC form 8
2024-01-18 00:00 ET
Ikena Oncology, Inc. published news for 2023 q4
SEC form 8
2024-01-18 00:00 ET
Ikena Oncology, Inc. published news for 2023 q4
SEC form 10
2023-11-09 07:30 ET
Ikena Oncology, Inc. reported for 2023 q3
SEC form 8
2023-11-09 07:09 ET
Ikena Oncology, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Ikena Oncology, Inc. reported for 2023 q3
SEC form 10
2023-08-10 07:00 ET
Ikena Oncology, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Ikena Oncology, Inc. reported for 2023 q2
SEC form 6
2023-08-07 08:02 ET
Ikena Oncology, Inc. published news for 2023 q2
SEC form 6
2023-06-30 17:15 ET
Ikena Oncology, Inc. published news for 2023 q1
SEC form 6
2023-05-15 09:09 ET
Ikena Oncology, Inc. published news for 2023 q1
SEC form 10
2023-05-15 06:04 ET
Ikena Oncology, Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Ikena Oncology, Inc. reported for 2023 q1
SEC form 6
2023-04-28 08:17 ET
Ikena Oncology, Inc. published news for 2023 q1
SEC form 6
2023-04-17 09:14 ET
Ikena Oncology, Inc. published news for 2023 q1
SEC form 10
2023-03-14 06:04 ET
Ikena Oncology, Inc. reported for 2022 q4
SEC form 10
2023-03-14 00:00 ET
Ikena Oncology, Inc. reported for 2022 q4
SEC form 6
2022-12-19 17:11 ET
Ikena Oncology, Inc. published news for 2022 q3
SEC form 6
2022-12-19 16:41 ET
Ikena Oncology, Inc. published news for 2022 q3
SEC form 6
2022-11-28 08:18 ET
Ikena Oncology, Inc. published news for 2022 q3
SEC form 6
2022-11-10 09:11 ET
Ikena Oncology, Inc. published news for 2022 q3
SEC form 10
2022-11-07 07:31 ET
Ikena Oncology, Inc. reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Ikena Oncology, Inc. reported for 2022 q3
SEC form 10
2022-08-11 06:03 ET
Ikena Oncology, Inc. reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Ikena Oncology, Inc. reported for 2022 q2
SEC form 6
2022-06-10 07:46 ET
Ikena Oncology, Inc. published news for 2022 q1
SEC form 10
2022-05-12 06:02 ET
Ikena Oncology, Inc. reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Ikena Oncology, Inc. reported for 2022 q1
SEC form 6
2022-04-27 16:32 ET
Ikena Oncology, Inc. published news for 2022 q1
SEC form 6
2022-04-25 18:48 ET
Ikena Oncology, Inc. published news for 2022 q1
SEC form 6
2022-04-13 07:01 ET
Ikena Oncology, Inc. published news for 2022 q1
SEC form 6
2022-04-06 07:04 ET
Ikena Oncology, Inc. published news for 2022 q1
SEC form 10
2022-03-17 06:31 ET
Ikena Oncology, Inc. published news for 2021 q4
SEC form 10
2022-03-17 00:00 ET
Ikena Oncology, Inc. published news for 2021 q4
SEC form 6
2022-02-24 16:54 ET
Ikena Oncology, Inc. published news for 2021 q4
SEC form 6
2022-02-24 16:43 ET
Ikena Oncology, Inc. published news for 2021 q4
SEC form 6
2022-01-28 07:23 ET
Ikena Oncology, Inc. published news for 2021 q4
SEC form 6
2022-01-26 07:26 ET
Ikena Oncology, Inc. published news for 2021 q4
SEC form 6
2022-01-25 21:30 ET
Ikena Oncology, Inc. published news for 2021 q4
SEC form 6
2021-11-23 20:58 ET
Ikena Oncology, Inc. published news for 2021 q3
SEC form 6
2021-11-10 16:39 ET
Ikena Oncology, Inc. published news for 2021 q3
SEC form 10
2021-11-10 06:05 ET
Ikena Oncology, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Ikena Oncology, Inc. published news for 2021 q3
SEC form 10
2021-08-12 16:21 ET
Ikena Oncology, Inc. published news for 2021 q2
SEC form 6
2021-08-12 10:43 ET
Ikena Oncology, Inc. published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Ikena Oncology, Inc. published news for 2021 q2
SEC form 10
2021-05-13 16:15 ET
Ikena Oncology, Inc. published news for 2021 q1
SEC form 6
2021-05-13 07:37 ET
Ikena Oncology, Inc. published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
Ikena Oncology, Inc. published news for 2021 q1
SEC form 6
2021-04-15 18:52 ET
Ikena Oncology, Inc. published news for 2021 q1
SEC form 6
2021-04-15 07:43 ET
Ikena Oncology, Inc. published news for 2021 q1
SEC form 6
2021-03-30 16:48 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:15 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:14 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:13 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:12 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:11 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:09 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:08 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:06 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 20:06 ET
Ikena Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-25 19:55 ET
Ikena Oncology, Inc. published news for 2020 q4